All Stories

  1. Human sex chromosome aneuploidies: The hypothalamic–pituitary–gonadal axis
  2. Testing for growth hormone deficiency in children
  3. Bio-Banding in Youth Sports: Background, Concept, and Application
  4. Low Risk of Adrenal Insufficiency After Use of Low- to Moderate-Potency Topical Corticosteroids for Children With Atopic Dermatitis
  5. Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium
  6. Testosterone Therapy in Adolescent Boys: The Need for a Structured Approach
  7. Should survivors of childhood cancer or testicular cancer be screened for androgen deficiency?
  8. Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies
  9. Short children born small for gestational age outcomes in the era of growth hormone therapy
  10. The Interconnected Histories of Endocrinology and Eligibility in Women’s Sport
  11. Evaluation of Hypothalamic-Pituitary-Adrenal Axis Suppression following Cutaneous Use of Topical Corticosteroids in Children: A Meta-Analysis
  12. Genes, Gender, Hormones, and Doping in Sport: A Convoluted Tale
  13. Cushing’s Disease in Children and Adolescents: Diagnosis and Management
  14. Treatment of growth hormone deficiency in children, adolescents and at the transitional age
  15. The Klinefelter syndrome: current management and research challenges
  16. Sperm retrieval in adolescent males with Klinefelter syndrome: medical and ethical issues
  17. Endocrine Responses to Exercise in the Developing Child and Adolescent
  18. Natesto™, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men
  19. Testis Development and Fertility Potential in Boys with Klinefelter Syndrome
  20. Biological maturation of youth athletes: assessment and implications
  21. Can Anabolic Steroids or Human Growth Hormone Affect the Growth and Maturation of Adolescent Athletes?
  22. Hurdling Over Sex? Sport, Science, and Equity
  23. Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement
  24. Etiologies and Early Diagnosis of Short Stature and Growth Failure in Children and Adolescents
  25. Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations
  26. A Multicenter, Open-Label, Observational Study of Testosterone Gel (1%) in the Treatment of Adolescent Boys With Klinefelter Syndrome or Anorchia
  27. 50 Years Ago in The Journal of Pediatrics
  28. 50 Years Ago in The Journal of Pediatrics
  29. 50 Years Ago in The Journal of Pediatrics
  30. Lactose Intolerance: Lack of Evidence for Short Stature or Vitamin D Deficiency in Prepubertal Children
  31. Children with Asymptomatic Short Stature: What Is an Appropriate Evaluation?
  32. Traumatic brain injury: endocrine consequences in children and adults
  33. Neuroendocrine alterations in the exercising human: Implications for energy homeostasis
  34. Role of Intensive Training in the Growth and Maturation of Artistic Gymnasts
  35. Biological markers of tissue-specific effects of GH therapy
  36. Testosterone exposure in childhood: discerning pathology from physiology
  37. Neuropsychological recovery and quality-of-life in children and adolescents with growth hormone deficiency following TBI: A preliminary study
  38. Recent updates on recombinant human growth hormone outcomes and adverse events
  39. Efficacy of IGF-based growth hormone (GH) dosing in nonGH-deficient (nonGHD) short stature children with low IGF-I is not related to basal IGF-I levels
  40. Prepubertal Children with Growth Hormone Deficiency Treated for Four Years with Growth Hormone Experience Dose-Dependent Increase in Height, but Not in the Rate of Puberty Initiation
  41. Biological assessment of abnormal genitalia
  42. Pediatricians and Hypothalamic/Pituitary Tumors: What is it about Them in Children and Adolescents that Alert us to their Presence?
  43. 50 Years Ago in The Journal of Pediatrics
  44. Diabetes Mellitus and Growth in Children and Adolescents
  45. 50 Years Ago in The Journal of Pediatrics
  46. Secondary exposure to testosterone from patients receiving replacement therapy with transdermal testosterone gels
  47. Stroke in a child with Adams-Oliver syndrome and mixed diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome
  48. How Does an Anabolic/Androgenic Steroid Get Banned from Sport Competition?
  49. Optimizing Potential for Fertility: Fertility Considerations for the Pediatrician
  50. Effects of short-course androgen therapy on the neurodevelopmental profile of infants and children with 49,XXXXY syndrome
  51. 50 Years Ago in The Journal of Pediatrics
  52. Sports, Hormones, and Doping in Children and Adolescents
  53. Traumatic Brain Injury in Children and Adolescents: Surveillance for Pituitary Dysfunction
  54. Variable Degree of Growth Hormone (GH) and Insulin-Like Growth Factor (IGF) Sensitivity in Children with Idiopathic Short Stature Compared with GH-Deficient Patients: Evidence from an IGF-Based Dosing Study of Short Children
  55. Ghrelin and growth hormone: Story in reverse
  56. Recombinant Insulin-Like Growth Factor (IGF)-I Treatment in Short Children with Low IGF-I Levels: First-Year Results from a Randomized Clinical Trial
  57. Clinical variability and novel neurodevelopmental findings in 49, XXXXY syndrome
  58. Current Indications for Growth Hormone Therapy for Children and Adolescents
  59. Drugs of abuse and the adolescent athlete
  60. Optimizing Potential for Fertility: Fertility Preservation Considerations for the Pediatric Endocrinologist
  61. Growth hormone and the adolescent athlete: What are the data for its safety and efficacy as an ergogenic agent?
  62. Position Stand on Androgen and Human Growth Hormone Use
  63. Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
  64. Sex Steroids, Growth Hormone, Leptin and the Pubertal Growth Spurt
  65. Recombinant human insulin-like growth factor-I therapy for children with growth disorders
  66. APPARENT GROWTH HORMONE DEFICIENCY IN CHILDREN WITH CEREBRAL PALSY
  67. Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop
  68. Reflections on Future Research in Adolescent Reproductive Health
  69. Growth hormone deficiency in children
  70. Idiopathic short stature: Definition, epidemiology, and diagnostic evaluation
  71. Idiopathic short stature: Management and growth hormone treatment
  72. Insulin Growth Factor-Based Dosing of Growth Hormone Therapy in Children: A Randomized, Controlled Study
  73. Male pubertal development and the role of androgen therapy
  74. Management of the Child Born Small for Gestational Age through to Adulthood: A Consensus Statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society
  75. Endocrinologie
  76. Puberty, Exercise and Bone Health
  77. Indicators of Biological Maturation and Secular Changes in Biological Maturation
  78. Persistent Hypercalcemia After Parathyroidectomy in an Adolescent and Effect of Treatment With Cinacalcet HCl
  79. Bone age and onset of puberty in normal boys
  80. Update of Newborn Screening and Therapy for Congenital Hypothyroidism
  81. Pharmacokinetic Studies of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I)/rhIGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome
  82. Increases in Overweight After Adenotonsillectomy in Overweight Children With Obstructive Sleep-Disordered Breathing Are Associated With Decreases in Motor Activity and Hyperactivity
  83. A Workshop on Pubertal Hormone Replacement Options in the United States
  84. Global Inequalities in Paediatric Endocrine Practice: Statement of Minimal Acceptable Care
  85. Single-center experience with pediatric Cushing's disease
  86. Pubertal alterations in growth and body composition: IX. Altered spontaneous secretion and metabolic clearance of growth hormone in overweight youth
  87. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose
  88. New facets of androgen replacement therapy during childhood and adolescence
  89. Reduced Physical Activity And Increased Overweight Following Adenotonsillectomy In Children With Obstructive Sleep Apnea
  90. Magnesium Deficiency Is Associated With Insulin Resistance in Obese Children
  91. Childhood Obesity
  92. Hormone Abuse in Adolescents and Adults
  93. Anthropometric factors associated with age of menarche: An analysis of two cohorts across five decades
  94. Endocrine Control of Body Composition in Infancy, Childhood, and Puberty
  95. Diminished Insulin Resistance with Weight Loss in Severely Overweight Youth
  96. Klinefelter syndrome: Expanding the phenotype and identifying new research directions
  97. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins pediatric endocrinology society drug and therapeutics committee
  98. Growth, body composition and hormonal axes in children and adolescents
  99. Delayed Onset of Pubertal Development in Children and Adolescents With Perinatally Acquired HIV Infection
  100. Relationship of Leptin to Bone Mineralization in Children and Adolescents
  101. Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy?
  102. Growth at puberty
  103. Androgens and puberty
  104. XXY
  105. Pubertal alterations in growth and body composition. VI. Pubertal insulin resistance: relation to adiposity, body fat distribution and hormone release
  106. Consequences of sport training during puberty
  107. D-chiro-inositol (INS-1) enhances ovulatory rate in hyperandrogenemic, oligomenorrheic women with the polycystic ovary syndrome.
  108. Lipoid Congenital Adrenal Hyperplasia (CAH): Patient Report and a Mini-Review
  109. Alterations in body composition and fat distribution in growth hormone—Deficient prepubertal children during growth hormone therapy
  110. Early menarche and adult height: Reprise of the hare and the tortoise?
  111. The Insulin-Like Growth Factor System in Kidney Diseases
  112. Alterations in growth and body composition during puberty. IV. Energy intake estimated by the Youth-Adolescent Food-Frequency Questionnaire: validation by the doubly labeled water method
  113. Pubertal alterations in growth and body composition. V. Energy expenditure, adiposity, and fat distribution
  114. Adrenomedullary Dysplasia and Hypofunction in Patients with Classic 21-Hydroxylase Deficiency
  115. Growth Hormone Stimulation Testing in Both Short and Normal Statured Children: Use of an Immunofunctional Assay
  116. Growth and pubertal development in children and adolescents: effects of diet and physical activity
  117. Longitudinal changes in growth hormone secretory process irregularity assessed transpubertally in healthy boys
  118. Sex steroid and growth hormone supplementation to enhance performance in adolescent athletes
  119. Gender and Sexual Maturation-Dependent Contrasts in the Neuroregulation of Growth Hormone Secretion in Prepubertal and Late Adolescent Males and Females--A General Clinical Research Center-Based Study
  120. Spontaneous and GnRH-provoked gonadotropin secretion and testosterone response to human chorionic gonadotropin in adolescent boys with thalassaemia major and delayed puberty
  121. Longitudinal assessment of hormonal and physical alterations during normal puberty in boys. VI. Modeling of growth velocity, mean growth hormone (GH mean), and serum testosterone (T) concentrations
  122. ROLE OF LEPTIN DURING CHILDHOOD GROWTH AND DEVELOPMENT
  123. Spontaneous and provoked growth hormone (GH) secretion and insulin-like growth factor I (IFG-I) concentration in patients with beta thalassaemia and delayed growth
  124. Evidence Supporting an AdipoLeptin-Growth Hormone Axis in Obesity-Related Hyposomatotropism
  125. Growth Hormone Deficiency in a Child with Sarcoidosis
  126. Androgen replacement in children with constitutional delay of puberty: The case for aggressive therapy
  127. Discordant phenotypes and 45,X/46,X,idic(Y).
  128. An immunofunctional GH assay: Use in children
  129. Repeated bouts of exercise alter the blood lactate-RPE relation
  130. Discordant Puberty in Monozygotic Twin Sisters with Neurofibromatosis Type 1 (NFl)
  131. Alterations in Growth and Body Composition During Puberty: III. Influence of Maturation, Gender, Body Composition, Fat Distribution, Aerobic Fitness, and Energy Expenditure on Nocturnal Growth Hormone Release
  132. Human growth hormone response to repeated bouts of aerobic exercise
  133. Estrogen and Testosterone, But Not a Nonaromatizable Androgen, Direct Network Integration of the Hypothalamo-Somatotrope (Growth Hormone)-Insulin-Like Growth Factor I Axis in the Human: Evidence from Pubertal Pathophysiology and Sex-Steroid Hormone Rep...
  134. Comparison of Pulsatile Luteinizing Hormone Secretion Between Prepubertal Children and Young Adults: Evidence for a Mass/Amplitude-Dependent Difference Without Gender or Day/Night Contrasts
  135. Exercise and growth hormone: Does one affect the other?
  136. Partial growth-hormone insensitivity: The role of growth-hormone receptor mutations in idiopathic short stature
  137. A Longitudinal Assessment of Hormonal and Physical Alterations during Normal Puberty in Boys. V. Rising Leptin Levels May Signal the Onset of Puberty
  138. Maturation of the Regulation of Growth Hormone Secretion in Young Males with Hypogonadotropic Hypogonadism Pharmacologically Exposed to Progressive Increments in Serum Testosterone
  139. Serum Lipid Levels and Steroidal Hormones in Women Runners With Irregular Menses
  140. The Short-Term Infusion of Ovine Corticotropin-Releasing Hormone Does Not Alter Luteinizing Hormone Concentrations in Young Adult Men
  141. A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. III. The neuroendocrine growth hormone axis during late prepuberty
  142. A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. II. Estrogen levels as determined by an ultrasensitive bioassay
  143. GROWTH HORMONES AND SEX STEROID INTERACTIONS AT PUBERTY
  144. Mode of pulsatile follicle-stimulating hormone secretion in gonadal hormone-sufficient and -deficient women--a clinical research center study
  145. National Cooperative Growth Study substudy II: Do growth hormone levels from serial sampling add important diagnostic information?
  146. Sex Steroids, Growth Hormone, Insulin-Like Growth Factor-1: Neuroendocrine and Metabolic Regulation in Puberty
  147. Radiological Case of the Month
  148. Absent pituitary gland in two brothers with an oral-facial-digital syndrome resembling OFDS II and VI: A new type of OFDS?
  149. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited
  150. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis
  151. Growth Hormone Secretory Dynamics During Puberty
  152. Regulatory Actions of Testosterone on Pulsatile Growth Hormone Secretion in the Human: Studies Using Deconvolution Analysis
  153. Dexamethasone therapy for isosexual precocious pseudopuberty caused by generalized glucocorticoid resistance
  154. Gonadal steroid hormone regulation of the somatotropic axis during puberty in humans
  155. Case 2
  156. Growth at puberty: interaction of androgens and growth hormone
  157. An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the Gs alpha-subunit from a bone lesion
  158. Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: effects of gender
  159. Androgen-Receptor Blockade Enhances Pulsatile Luteinizing Hormone Production in Late Pubertal Males: Evidence for a Hypothalamic Site of Physiologic Androgen Feedback Action
  160. Growth and the Child with Diabetes Mellitus
  161. Alterations in growth hormone secretion and clearance in adolescent boys with insulin-dependent diabetes mellitus
  162. A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. I. Serum growth hormone-binding protein
  163. Characterization of pulsatile secretion and clearance of plasma cortisol in premature and term neonates using deconvolution analysis
  164. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis
  165. Alterations in the neuroendocrine control of growth hormone secretion in the uremic rat
  166. Altered Growth Hormone Secretory Dynamics in Prepubertal Males with Constitutional Delay of Growth
  167. Long-Term Endurance Training Alters the Hypothalamic-Pituitary Axes for Gonadotropins and Growth Hormone
  168. Elevated Growth Hormone Secretory Rate in Premature Infants: Deconvolution Analysis of Pulsatile Growth Hormone Secretion in the Neonate
  169. Effects of opioid receptor blockade on luteinizing hormone (LH) pulses and interpuise LH concentrations in normal women during the early phase of the menstrual cycle
  170. The Effect of Training Intensity on Ratings of Perceived Exertion
  171. The impact of gonadal steroid hormone action on growth hormone secretion during childhood and adolescence
  172. Properties of spontaneous growth hormone secretory bursts and half-life of endogenous growth hormone in boys with idiopathic short stature. Genentech Collaborative Group
  173. Exercise Training at and above the Lactate Threshold in Previously Untrained Women
  174. Durability of the reproductive axis in eumenorrheic women during 1 yr of endurance training
  175. Anabolic-Androgenic Steroids and the Adolescent
  176. Contemporary aspects of discrete peak-detection algorithms. II. The paradigm of the luteinizing hormone pulse signal in women
  177. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass
  178. Exogenous Androgen Does Not Alter Hypothalamic Proopiomelanocortin Gene Transcript Levels in the Sexually Immature Male Rat
  179. Primary amenorrhea in two postpubertal girls with underlying malignancy
  180. Estrogenic Modulation of the Gonadotropin-Releasing Hormone-Stimulated Secretory Activity of the Gonadotrope and Lactotrope in Prepubertal Females with Turner's Syndrome*
  181. Letters to the Editor
  182. Function of the growth hormone-insulin-like growth factor I axis in the profoundly growth-retarded diabetic child: Evidence for defective target organ responsiveness in the Mauriac syndrome
  183. Growth Hormone-Binding Protein Activity Is Inversely Related to 24-Hour Growth Hormone Release in Normal Boys*
  184. Augmented Hypothalamic Proopiomelanocortin Gene Expression with Pubertal Development in the Male Rat: Evidence for an Androgen Receptor-Independent Action*
  185. Salpingitis in a sexually inactive adolescent with congenital virilizing adrenal hyperplasia
  186. Reliability of Estimates of Pulsatile Characteristics of Luteinizing Hormone and Growth Hormone Release in Women*
  187. Increased hGH Production Rate after Low-Dose Estrogen Therapy in Prepubertal Girls with Turner's Syndrome
  188. Testosterone and Oxandrolone, a Nonaromatizable Androgen, Specifically Amplify the Mass and Rate of Growth Hormone (GH) Secreted per Burst without Altering GH Secretory Burst Duration or Frequency or the GH Half-Life*
  189. Prediction of Lactate Threshold (LT) and Fixed Blood Lactate Concentrations (FBLC) from 3200-m Running Performance in Women*
  190. Physical Exercise and Menstrual Cycle Alterations
  191. Clinical Utility of Cycle Exercise for the Physiologic Assessment of Growth Hormone Release in Children
  192. Variations of Pulsatile Growth Hormone Release in Healthy Short Prepubertal Boys
  193. Growth Hormone-Releasing Hormone and Growth Hormone-Releasing Peptide as Potential Therapeutic Modalities
  194. Primary Cortisol Resistance Presenting as Isosexual Precocity*
  195. Atenolol Enhances Nocturnal Growth Hormone (GH) Release in GH-Deficient Children during Long Term GH-Releasing Hormone Therapy*
  196. Somatostatin Inhibition of Growth Hormone Secretion by Somatotropes from Male, Female, and Androgen Receptor-Deficient Rats: Evidence for Differing Sensitivities*
  197. Specific, Time-Dependent Actions of Low-Dose Ethinyl Estradiol Administration on the Episodic Release of Growth Hormone, Follicle-Stimulating Hormone, and Luteinizing Hormone in Prepubertal Girls with Turner's Syndrome *
  198. Serum Cortisol Concentrations in Children with Protein-Energy Malnutrition
  199. Alterations in the Pulsatile Properties of Circulating Growth Hormone Concentrations during Puberty in Boys*
  200. Growth Hormone Secretion by Individual Somatotropes of the Testicular Feminized Rat*
  201. Androgen-dependent somatotroph function in a hypogonadal adolescent male: Evidence for control of exogenous androgens on growth hormone release
  202. Percentages of Maximal Heart Rate, Heart Rate Reserve, and V̇O2peak for Determining Endurance Training Intensity in Sedentary Women*
  203. Prediction of Lactate Threshold and Fixed Blood Lactate Concentrations from 3200-m Time Trial Running Performance in Untrained Females*
  204. Treatment of the Young Child With Postoperative Central Diabetes Insipidus
  205. Enhanced clearance of vancomycin by hemodialysis in a child
  206. Acute Androgen Receptor Blockade Increases Luteinizing Hormone Secretory Activity in Men*
  207. A Persistent Pattern of Varying Pituitary Responsivity to Exogenous Growth Hormone (GH)-Releasing Hormone in GH-Deficient Children: Evidence Supporting Periodic Somatostatin Secretion*
  208. Acceleration of Growth Rate in Growth Hormone-Deficient Children Treated with Human Growth Hormone-Releasing Hormone
  209. Phosphatidylinositol-glycan anchors of membrane proteins: potential precursors of insulin mediators
  210. Atenolol Enhances Growth Hormone Release to Exogenous Growth Hormone-Releasing Hormone but Fails to Alter Spontaneous Nocturnal Growth Hormone Secretion in Boys with Constitutional Delay of Growth
  211. Contemporary Aspects of Discrete Peak-Detection Algorithms. I. The Paradigm of the Luteinizing Hormone Pulse Signal in Men*
  212. Physiological Profiles of Episodic Progesterone Release During the Midluteal Phase of the Human Menstrual Cycle: Analysis of Circadian and Ultradian Rhythms, Discrete Pulse Properties, and Correlations With Simultaneous Luteinizing Hormone Release*
  213. Prediction of Lactate Threshold and Fixed Blood Lactate Concentrations from 3200-m Running Performance in Male Runners
  214. Physiological Attributes of Episodic Testosterone Secretion
  215. Operating Characteristics of the Male Hypothalamo-Pituitary-Gonadal Axis: Pulsatile Release of Testosterone and Follicle-Stimulating Hormone and Their Temporal Coupling with Luteinizing Hormone*
  216. Actions of calcium ions and a calcium-influx blocker on basal and TRH- and GnRH-stimulated hormone release in patients with pituitary adenomas
  217. Modulating actions of estradiol on gonadotropin-releasing hormone—stimulated prolactin secretion in postmenopausal individuals
  218. Arginine-Induced Insulin and Growth Hormone Secretion in Children with Nutritional Rickets
  219. Sustained Inhibitory Actions of a Potent Antagonist of Gonadotropin-Releasing Hormone in Postmenopausal Women*
  220. Impact of intensive venous sampling on characterization of pulsatile GH release
  221. Selective β1-adrenergic receptor-blockade with atenolol enhances growth hormone releasing hormone and mediated growth hormone release in man
  222. Augmentation of Growth Hormone Secretion during Puberty: Evidence for a Pulse Amplitude-Modulated Phenomenon*
  223. Actions of estradiol on discrete attributes of the luteinizing hormone pulse signal in man. Studies in postmenopausal women treated with pure estradiol.
  224. Effects of Sex and Age on the 24-Hour Profile of Growth Hormone Secretion in Man: Importance of Endogenous Estradiol Concentrations*
  225. Response of Anterior Pituitary Cells to Culture Media
  226. Serum Insulin-Like Growth Factors I and II Concentrations and Growth Hormone and Insulin Responses to Arginine Infusion in Children with Protein-Energy Malnutrition before and after Nutritional Rehabilitation
  227. Endocrine impact of pure estradiol replacement in postmenopausal women: Alterations in anterior pituitary hormone release and circulating sex steroid hormone concentrations
  228. Partial Insulin Resistance in the Mouse BC3H-1 Cell Line: Absent Hexose-Independent Actions of Insulin*
  229. Appraising Endocrine Pulse Signals at Low Circulating Hormone Concentrations: Use of Regional Coefficients of Variation in the Experimental Series To Analyze Pulsatile Luteinizing Hormone Release
  230. Role of Endogenous Opiates in Pubertal Maturation: Opposing Actions of Naltrexone in Prepubertal and Late Pubertal Boys*
  231. Pituitary self-priming actions of gonadotropin-releasing hormone. Kinetics of estradiol's potentiating effects on gonadotropin-releasing hormone-facilitated luteinizing hormone and follicle-stimulating hormone release in healthy postmenopausal women.
  232. Physiological Properties of the Luteinizing Hormone Pulse Signal: Impact of Intensive and Extended Venous Sampling Paradigms on Its Characterization in Healthy Men and Women*
  233. Failure to Detect the “Dawn Phenomenon” in Nondiabetic Subjects with Markedly Different Patterns of Nocturnal Growth Hormone Secretion*
  234. Metabolic clearance of biologically active luteinizing hormone in man.
  235. The Effect of Androgens on the Pulsatile Release and the Twenty-Four-Hour Mean Concentration of Growth Hormone in Peripubertal Males*
  236. Carbamazkpine Toxicity: Comparison of Measurement of Drug Levels by HPLC and Emit and Model of Carbamazepine Kinetics
  237. Clinical Studies with GHRH in Man
  238. Endogenous Opiates Participate in the Regulation of Pulsatile Luteinizing Hormone Release in an Unopposed Estrogen Milieu: Studies in Estrogen-Replaced, Gonadectomized Patients with Testicular Feminization*
  239. Exercise-Induced Menstrual Disorders
  240. Altered Neuroendocrine Regulation of Gonadotropin Secretion in Women Distance Runners*
  241. Pathophysiology of Male Hypogonadism Associated with Endogenous Hyperestrogenism
  242. Growth Hormone Releasing Hormone and Growth Hormone: Genetic Studies in Familial Growth Hormone Deficiency
  243. Phorbol esters affect pituitary growth hormone (GH) and prolactin release: The interaction with GH releasing factor, somatostatin and bromocriptine
  244. 464 TESTOSTERONE (T) BUT NOT OXANDROLONE (OX) INCREASES SPONTANEOUS GROWTH HORMONE (GH) AND SOMATOMEDIN-C (SmC) CONCENTRATIONS IN BOYS WITH CONSTITUTIONAL DELAY OF GROWTH AND ADOLESCENCE (CDGA)
  245. 468 AMINO ACID RESIDUES 93–96 OF THE HUMAN GROWTH HORMONE MOLECULE ARE IMPORTANT FOR POLYCLONAL ANTISERUM RECOGNITION
  246. Minimizing false-positive errors in hormonal pulse detection
  247. Agents that increase cellular cyclic AMP or calcium stimulate prolactin release from the 235-1 pituitary cell line
  248. Human pancreatic tumor GH-releasing factor
  249. Acceleration of Growth in Two Children Treated with Human Growth Hormone-Releasing Factor
  250. Divergent Influences of the Structurally Dissimilar Calcium Entry Blockers, Diltiazem and Verapamil, on Thyrotropin- and Gonadotropin-Releasing Hormone- Stimulated Anterior Pituitary Hormone Secretion in Man*
  251. Crossed Fused Ectopia with a Blind Left Ureter in a Young Woman with Turner’s Syndrome: Sonographic and Radiological Demonstration of a Previously Undescribed Variant
  252. Modulation of the Pulsatile Release of Biologically Active Luteinizing Hormone by Endogenous Opiates
  253. Sex Differences in the Cyclic Adenosine 3′:5′-Monophosphate and Growth Hormone Response to Growth Hormone-Releasing Factor In Vitro
  254. Effects of Human Pancreatic Growth Hormone-Releasing Factor-40 on Serum Growth Hormone, Prolactin, Luteinizing Hormone, Follicle-Stimulating Hormone, and Somatomedin-C Concentrations in Normal Women throughout the Menstrual Cycle*
  255. Mesulergine, a new dopamine agonist: Effects on anterior pituitary function and kinetics
  256. Growth Hormone Release in Response to Human Pancreatic Tumor Growth Hormone-Releasing Hormone-40 in Children with Short Stature*
  257. Anti-insulin-like (diabetogenic) peptides in pituitary extracts: Role of oxytocin
  258. Oxytocin: Anti-insulin-like effects in isolated fat cells
  259. Performance of LH pulse-detection algorithms at rapid rates of venous sampling in humans
  260. Intensified Rates of Venous Sampling Unmask the Presence of Spontaneous, High-Frequency Pulsations of Luteinizing Hormone in Man*
  261. Divergent Influences of Calcium Ions on Releasing Factor-Stimulated Anterior Pituitary Hormone Secretion in Normal Man*
  262. Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man.
  263. The Effect of Exogenous Growth Hormone on Insulin Requirements during Closed Loop Insulin Delivery in Insulin-Dependent Diabetes Mellitus
  264. Human Pancreatic Tumor Growth Hormone-Releasing Factor: Dose-Response Relationships in Normal Man*
  265. Follicle-Stimulating Hormone-Secreting Pituitary Tumor with Concomitant Elevation of Serum α-Subunit Levels*
  266. Generalized Convulsions as the Presenting Sign of Amoxapine Intoxication
  267. Reversible growth hormone deficiency and delayed puberty triggered by a stressful experience in a young adult
  268. Human Pancreatic Tumor Growth Hormone (GH)-Releasing Factor and Cyclic Adenosine 3′,5′-Monophosphate Evoke GH Release from Anterior Pituitary Cells: The Effects of Pertussis Toxin, Cholera Toxin, Forskolin, and Cycloheximide*
  269. Autoimmunity in congenital rubella syndrome
  270. Effect of Testosterone on Somatomedin-C Concentrations in Prepubertal Boys*
  271. Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome
  272. Doα-Adrenergic Mechanisms Regulate Spontaneous or Opiate-Modulated Pulsatile Luteinizing Hormone Secretion in Man?*
  273. Endogenous opiates modulate the pulsatile secretion of biologically active luteinizing hormone in man.
  274. Prolactin secretion by human chorion-decidua in vitro: Influences of mode of delivery and agents that modify prostaglandin synthesis
  275. Pertussis Toxin Blocks the Somatostatin-Induced Inhibition of Growth Hormone Release and Adenosine 3′,5′ -Monophosphate Accumulation*
  276. Naloxone Attenuates Recovery from Insulin-Induced Hypoglycemia in Normal Man*
  277. Reply
  278. The syndrome of anosmia with hypogonadotropic hypogonadism: A genetic study of 18 new families and a review
  279. Preliminary data on the dexamethasone suppression test in children with major depressive disorder
  280. Severe metabolic complications in a cross-country runner with sickle cell trait
  281. Luteinizing Hormone Secretion Is Enhanced by Pertussis Toxin, Cholera Toxin, and Forskolin
  282. Apomorphine response and subtyping of schizophrenia
  283. HUMAN PANCREATIC GROWTH-HORMONE-RELEASING FACTOR SELECTIVELY STIMULATES GROWTH-HORMONE SECRETION IN MAN
  284. Somatotroph Hyperplasia
  285. Tolmetin sodium in the management of nephrogenic diabetes insipidus
  286. Prolactin binding sites on human chorion-decidua tissue
  287. Syndrome of anosmia with hypogonadotropic hypogonadism (kallmann syndrome)
  288. SELECTIVE GROWTH HORMONE AND CYCLIC AMP STIMULATING ACTIVITY IS PRESENT IN A HUMAN PANCREATIC ISLET CELL TUMOR
  289. Naloxone in chronic schizophrenic patients: Neuroendocrine and behavioral effects
  290. Insulin binding to the HL-60 human promyelocytic cell line
  291. Reproductive system function in women cross-country runners
  292. Pergolide Mesylate: Its Effects on Circulating Anterior Pituitary Hormones in Man*
  293. Rapid Changes of Prolactinoma Volume after Withdrawal and Reinstitution of Bromocriptine*
  294. Effect of acetate on glucose utilization by isolated rat thymocytes
  295. Dopaminergic Mechanisms and Luteinizing Hormone (LH) Secretion. II. Differential Effects of Dopamine and Bromocriptine on LH Release in Normal Women*
  296. Unusual heterogeneity of circulating prolactin in an acromegalic
  297. Effect of Ammonia on Glucose Oxidation by Isolated Rat Adipocytes
  298. Prolactin response to beta-endorphin in man
  299. Rapid Regression of Pituitary Prolactinomas during Bromocriptine Treatment*
  300. HLA-Compatible Paternity in Two “Fertile Eunuchs” with Congenital Hypogonadotropic Hypogonadism and Anosmia (the Kallmann Syndrome)
  301. Failure of Cortisol Blockade to Inhibit Early Morning Increases in Basal Insulin Requirements in Fasting Insulin-dependent Diabetics
  302. A Broad Spectrum of Prolactin Suppression by Bromocriptine in Hyperprolactinemic Women: A Study of Serum Prolactin and Bromocriptine Levels after Acute and Chronic Administration ofBromocriptine*
  303. Dopaminergic Mechanisms and Luteinizing Hormone Secretion. I. Acute Administration of the Dopamine Agonist Bromocriptine Does Not Inhibit Luteinizing Hormone Release in Hyperprolactinemic Women*
  304. A correlation between platelet monoamine oxidase activity and plasma prolactin concentrations in man
  305. Indirect Immunofluorescent Localization of Prolactin to the Cytoplasm of Decidua and Trophoblast Cells in Human Placental Membranes at Term
  306. Prolactin and pituitary tumors
  307. Congenital Anosmia: Detection Thresholds for Seven Odorant Classes in Hypogonadal and Eugonadal Patients
  308. Thyroid-Stimulating Hormone and Prolactin Responses to Thyrotropin-Releasing Hormone during Infusion of Epinephrine and Propranolol in Man
  309. Effect of prolactin on dopamine synthesis in medial basal hypothalamus: Evidence for a short loop feedback
  310. The Relationship of the Bovine Pituitary "Diabetogenic Peptide" to Prolactin
  311. Serum Prolactin Concentration in a Prepubertal Boy With Gynecomastia
  312. PROPRANOLOL AND PROLACTIN
  313. Fatal ECHO 24 infection in a patient with hypogammaglobulinemia: Relationship to dermatomyositis-like syndrome
  314. Characterization of Growth Hormone and Prolactin Produced by Human Pituitary in Culture
  315. EFFECT OF CYPROHEPTADINE ON TRH-STIMULATED PROLACTIN AND TSH RELEASE IN MAN1 2 3
  316. Congenital hypothyroidism in a young man with growth hormone, thyrotropin, and prolactin deficiencies
  317. Radioiodinated Human Pituitary and Amniotic Fluid Prolactins with Preserved Molecular Integrity
  318. Response to LH-RH and Clomiphene Citrate in Two Women with the Prader-Labhart-Willi Syndrome
  319. Charge Properties of Human Pituitapy and Amniotic Fluid Prolactins
  320. Alteration of Human and Bovine Prolactins by a Chloramine T Radioiodination: Comparison with Lactoperoxidase-Iodinated Prolactins
  321. PROLACTIN OF APPARENT LARGE MOLECULAR SIZE: THE MAJOR IMMUNOACTIVE PROLACTIN COMPONENT IN PLASMA OF A PATIENT WITH A PITUITARY TUMOR1
  322. HETEROGENEITY OF RESPONSE TO LH-RH IN PATIENTS WITH THE SYNDROME OF CONGENITAL ANOSMIA AND HYPOGONADISM